{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:09:46Z","timestamp":1779293386209,"version":"3.51.4"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["1170893"],"award-info":[{"award-number":["1170893"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["1171463"],"award-info":[{"award-number":["1171463"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["1151008"],"award-info":[{"award-number":["1151008"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["11180987"],"award-info":[{"award-number":["11180987"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002850","name":"Fondo Nacional de Desarrollo Cient\u00edfico y Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["1160800"],"award-info":[{"award-number":["1160800"]}],"id":[{"id":"10.13039\/501100002850","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Instituto Milenio","award":["IMII P09\/016-F"],"award-info":[{"award-number":["IMII P09\/016-F"]}]},{"name":"Direcci\u00f3n de Investigaci\u00f3n Medicina-UC","award":["16-240"],"award-info":[{"award-number":["16-240"]}]},{"DOI":"10.13039\/501100002848","name":"Comisi\u00f3n Nacional de Investigaci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["21140027"],"award-info":[{"award-number":["21140027"]}],"id":[{"id":"10.13039\/501100002848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Gallbladder cancer (GBC) is the most common tumor of the biliary tract. The incidence of GBC shows a large geographic variability, being particularly frequent in Native American populations. In Chile, GBC represents the second cause of cancer-related death among women. We describe here the establishment of three novel cell lines derived from the ascitic fluid of a Chilean GBC patient, who presented 46% European, 36% Mapuche, 12% Aymara and 6% African ancestry.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>After immunocytochemical staining of the primary cell culture, we isolated and comprehensively characterized three independent clones (PUC-GBC1, PUC-GBC2 and PUC-GBC3) by short tandem repeat DNA profiling and RNA sequencing as well as karyotype, doubling time, chemosensitivity, in vitro migration capability and in vivo tumorigenicity assay. Primary culture cells showed high expression of CK7, CK19, CA 19-9, MUC1 and MUC16, and negative expression of mesothelial markers. The three isolated clones displayed an epithelial phenotype and an abnormal structure and number of chromosomes. RNA sequencing confirmed the increased expression of cytokeratin and mucin genes, and also of <jats:italic>TP53<\/jats:italic> and <jats:italic>ERBB2<\/jats:italic> with some differences among the three cells lines, and revealed a novel exonic mutation in <jats:italic>NF1<\/jats:italic>. The PUC-GBC3 clone was the most aggressive according to histopathological features and the tumorigenic capacity in NSG mice.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The first cell lines established from a Chilean GBC patient represent a new model for studying GBC in patients of Native American descent.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s40659-020-00282-7","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T10:03:05Z","timestamp":1586944985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Functional and genomic characterization of three novel cell lines derived from a metastatic gallbladder cancer tumor"],"prefix":"10.1186","volume":"53","author":[{"given":"Patricia","family":"Garc\u00eda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Bizama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime A.","family":"Espinoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helga","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Cerda-Infante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianela","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana P.","family":"Montecinos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justo","family":"Lorenzo-Bermejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Boekstegers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcela","family":"D\u00e1vila-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisca","family":"Alfaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Leiva-Acevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zasha","family":"Parra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumie","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Leal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcela","family":"Lagos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8313-8774","authenticated-orcid":false,"given":"Juan Carlos","family":"Roa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"issue":"6","key":"282_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492(Epub 2018\/09\/13).","journal-title":"CA Cancer J Clin"},{"key":"282_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/clep.s37357","volume":"6","author":"R Hundal","year":"2014","unstructured":"Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99\u2013109. https:\/\/doi.org\/10.2147\/clep.s37357(Epub 2014\/03\/19).","journal-title":"Clin Epidemiol"},{"issue":"5","key":"282_CR3","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359\u201386. https:\/\/doi.org\/10.1002\/ijc.29210(Epub 2014\/09\/16).","journal-title":"Int J Cancer"},{"key":"282_CR4","unstructured":"Series y Gr\u00e1ficos de Mortalidad. Ministerio de Salud. http:\/\/www.deis.cl\/series-y-graficos-de-mortalidad\/. Accessed 05 Feb 2019."},{"key":"282_CR5","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3332\/ecancer.2016.704","volume":"10","author":"L Villanueva","year":"2016","unstructured":"Villanueva L. Cancer of the gallbladder-Chilean statistics. Ecancer Med Sci. 2016;10:704. https:\/\/doi.org\/10.3332\/ecancer.2016.704(Epub 2017\/01\/21).","journal-title":"Ecancer Med Sci."},{"issue":"5","key":"282_CR6","doi-asserted-by":"publisher","first-page":"e1006756","DOI":"10.1371\/journal.pgen.1006756","volume":"13","author":"J Lorenzo Bermejo","year":"2017","unstructured":"Lorenzo Bermejo J, Boekstegers F, Gonzalez Silos R, Marcelain K, Baez Benavides P, Barahona Ponce C, et al. Subtypes of Native American ancestry and leading causes of death: Mapuche ancestry-specific associations with gallbladder cancer risk in Chile. PLoS Genet. 2017;13(5):e1006756. https:\/\/doi.org\/10.1371\/journal.pgen.1006756(Epub 2017\/05\/26).","journal-title":"PLoS Genet"},{"issue":"7","key":"282_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.4103\/1947-2714.98586","volume":"4","author":"A Andren-Sandberg","year":"2012","unstructured":"Andren-Sandberg A. Diagnosis and management of gallbladder cancer. N Am J Med Sci. 2012;4(7):293\u20139. https:\/\/doi.org\/10.4103\/1947-2714.98586(Epub 2012\/08\/07).","journal-title":"N Am J Med Sci."},{"issue":"6","key":"282_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3322\/canjclin.51.6.349","volume":"51","author":"EC Lazcano-Ponce","year":"2001","unstructured":"Lazcano-Ponce EC, Miquel JF, Munoz N, Herrero R, Ferrecio C, Wistuba II, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51(6):349\u201364.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"282_CR9","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/ijc.21683","volume":"118","author":"G Randi","year":"2006","unstructured":"Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006;118(7):1591\u2013602. https:\/\/doi.org\/10.1002\/ijc.21683.","journal-title":"Int J Cancer"},{"key":"282_CR10","volume-title":"AJCC Cancer Staging Atlas","year":"2012","unstructured":"Compton CC, Byrd DR, Garcia-Aguilar J, Kurtzman SH, Olawaiye A, Washington MK, editors. AJCC Cancer Staging Atlas. 2nd ed. New York: Springer-Verlag; 2012.","edition":"2"},{"issue":"2","key":"282_CR11","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1365-2559.2008.03192.x","volume":"55","author":"RD Goldin","year":"2009","unstructured":"Goldin RD, Roa JC. Gallbladder cancer: a morphological and molecular update. Histopathology. 2009;55(2):218\u201329. https:\/\/doi.org\/10.1111\/j.1365-2559.2008.03192.x(Epub 2009\/06\/06).","journal-title":"Histopathology"},{"issue":"1","key":"282_CR12","first-page":"95","volume":"1","author":"S Homma","year":"1988","unstructured":"Homma S, Hasumura S, Nagamori S, Kameda H. Establishment and characterization of a human gall bladder carcinoma cell line NOZ. Hum Cell. 1988;1(1):95\u20137 (Epub 1988\/03\/01).","journal-title":"Hum Cell"},{"issue":"4","key":"282_CR13","first-page":"574","volume":"71","author":"S Koyama","year":"1980","unstructured":"Koyama S, Yoshioka T, Mizushima A, Kawakita I, Yamagata S, Fukutomi H, et al. Establishment of a cell line (G-415) from a human gallbladder carcinoma. Gan. 1980;71(4):574\u20135 (Epub 1980\/08\/01).","journal-title":"Gan."},{"issue":"7","key":"282_CR14","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/j.1349-7006.1995.tb02450.x","volume":"86","author":"H Shimura","year":"1995","unstructured":"Shimura H, Date K, Matsumoto K, Nakamura T, Tanaka M. Induction of invasive growth in a gallbladder cancer cell line by hepatocyte growth factor in vitro. Jpn J Cancer Res. 1995;86(7):662\u20139 (Epub 1995\/07\/01).","journal-title":"Jpn J Cancer Res"},{"issue":"5","key":"282_CR15","first-page":"1189","volume":"24","author":"M Ghosh","year":"2004","unstructured":"Ghosh M, Koike N, Yanagimoto G, Tsunoda S, Kaul S, Hirano T, et al. Establishment and characterization of unique human gallbladder cancer cell lines. Int J Oncol. 2004;24(5):1189\u201396 (Epub 2004\/04\/07).","journal-title":"Int J Oncol"},{"issue":"6","key":"282_CR16","first-page":"1251","volume":"10","author":"N Yamada","year":"1997","unstructured":"Yamada N, Chung Y, Ohtani H, Ikeda T, Onoda N, Sawada T, et al. Establishment and characterization of a new human gallbladder carcinoma cell line (OCUG-1) producing TA-4. Int J Oncol. 1997;10(6):1251\u20135 (Epub 1997\/06\/01).","journal-title":"Int J Oncol"},{"issue":"2","key":"282_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/sj.bjc.6600440","volume":"87","author":"JL Ku","year":"2002","unstructured":"Ku JL, Yoon KA, Kim IJ, Kim WH, Jang JY, Suh KS, et al. Establishment and characterisation of six human biliary tract cancer cell lines. Br J Cancer. 2002;87(2):187\u201393. https:\/\/doi.org\/10.1038\/sj.bjc.6600440(Epub 2002\/07\/11).","journal-title":"Br J Cancer"},{"issue":"3","key":"282_CR18","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3892\/or.2011.1570","volume":"27","author":"JH Wang","year":"2012","unstructured":"Wang JH, Li LF, Yu Y, Li B, Jin HJ, Shen DH, et al. Establishment and characterization of a cell line, EH-GB2, derived from hepatic metastasis of gallbladder cancer. Oncol Rep. 2012;27(3):775\u201382. https:\/\/doi.org\/10.3892\/or.2011.1570(Epub 2011\/12\/03).","journal-title":"Oncol Rep"},{"key":"282_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12935-017-0388-8","volume":"17","author":"ZY Liu","year":"2017","unstructured":"Liu ZY, Xu GL, Tao HH, Yang YQ, Fan YZ. Establishment and characterization of a novel highly aggressive gallbladder cancer cell line, TJ-GBC2. Cancer Cell Int. 2017;17:20. https:\/\/doi.org\/10.1186\/s12935-017-0388-8(Epub 2017\/02\/15).","journal-title":"Cancer Cell Int"},{"issue":"8","key":"282_CR20","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/j.1440-1827.1997.tb04535.x","volume":"47","author":"T Itoi","year":"1997","unstructured":"Itoi T, Watanabe H, Yoshida M, Ajioka Y, Nishikura K, Saito T. Correlation of p53 protein expression with gene mutation in gall-bladder carcinomas. Pathol Int. 1997;47(8):525\u201330 (Epub 1997\/08\/01).","journal-title":"Pathol Int"},{"issue":"3","key":"282_CR21","first-page":"251","volume":"128","author":"I Roa","year":"2000","unstructured":"Roa I, Melo A, Roa J, Araya J, Villaseca M, de Aretxabala X. P53 gene mutation in gallbladder cancer. Rev Med Chil. 2000;128(3):251\u20138 (Epub 2000\/08\/30).","journal-title":"Rev Med Chil"},{"issue":"4","key":"282_CR22","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S1072-7515(01)01012-2","volume":"193","author":"ZW Quan","year":"2001","unstructured":"Quan ZW, Wu K, Wang J, Shi W, Zhang Z, Merrell RC. Association of p53, p16, and vascular endothelial growth factor protein expressions with the prognosis and metastasis of gallbladder cancer. J Am Coll Surg. 2001;193(4):380\u20133 (Epub 2001\/10\/05).","journal-title":"J Am Coll Surg"},{"issue":"1","key":"282_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4103\/1319-3767.105922","volume":"19","author":"M Ghosh","year":"2013","unstructured":"Ghosh M, Sakhuja P, Singh S, Agarwal AK. p53 and beta-catenin expression in gallbladder tissues and correlation with tumor progression in gallbladder cancer. Saudi J Gastroenterol. 2013;19(1):34\u20139. https:\/\/doi.org\/10.4103\/1319-3767.105922(Epub 2013\/01\/16).","journal-title":"Saudi J Gastroenterol."},{"issue":"2","key":"282_CR24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s12253-013-9710-5","volume":"20","author":"K Kim","year":"2014","unstructured":"Kim K, Kim DH, Chae SW, Shin JH, Kim HJ, Do SI, et al. Expression of cell cycle-related proteins, p16, p53 and p63 as important prognostic markers in gallbladder adenocarcinoma. Pathol Oncol Res. 2014;20(2):409\u201315. https:\/\/doi.org\/10.1007\/s12253-013-9710-5(Epub 2013\/11\/02).","journal-title":"Pathol Oncol Res."},{"issue":"6","key":"282_CR25","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1159\/000450999","volume":"91","author":"A Singh","year":"2016","unstructured":"Singh A, Mishra PK, Saluja SS, Talikoti MA, Kirtani P, Najmi AK. Prognostic significance of HER-2 and p53 expression in gallbladder carcinoma in North Indian patients. Oncology. 2016;91(6):354\u201360. https:\/\/doi.org\/10.1159\/000450999(Epub 2016\/10\/27).","journal-title":"Oncology."},{"issue":"6","key":"282_CR26","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703\u201313. https:\/\/doi.org\/10.1038\/nm.4333(Epub 2017\/05\/10).","journal-title":"Nat Med"},{"issue":"4","key":"282_CR27","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00428-015-1898-1","volume":"468","author":"H Yoshida","year":"2016","unstructured":"Yoshida H, Shimada K, Kosuge T, Hiraoka N. A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status. Virchows Arch. 2016;468(4):431\u20139. https:\/\/doi.org\/10.1007\/s00428-015-1898-1(Epub 2016\/01\/14).","journal-title":"Virchows Arch"},{"key":"282_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-018-0162-8","author":"S Halder","year":"2018","unstructured":"Halder S, Kundu S, Chakraborty J, Chakrabarti S. Significance of HER2 and Ki-67 in preneoplastic lesions and carcinoma of gallbladder. J Gastrointest Cancer. 2018. https:\/\/doi.org\/10.1007\/s12029-018-0162-8(Epub 2018\/08\/30).","journal-title":"J Gastrointest Cancer."},{"issue":"1","key":"282_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0165-4608(01)00386-7","volume":"128","author":"J Tapper","year":"2001","unstructured":"Tapper J, Kettunen E, El-Rifai W, Seppala M, Andersson LC, Knuutila S. Changes in gene expression during progression of ovarian carcinoma. Cancer Genet Cytogenet. 2001;128(1):1\u20136. https:\/\/doi.org\/10.1016\/s0165-4608(01)00386-7(Epub 2001\/07\/17).","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"282_CR30","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1186\/s12885-019-6470-y","volume":"19","author":"H Yue","year":"2019","unstructured":"Yue H, Wang J, Chen R, Hou X, Li J, Lu X. Gene signature characteristic of elevated stromal infiltration and activation is associated with increased risk of hematogenous and lymphatic metastasis in serous ovarian cancer. BMC Cancer. 2019;19(1):1266. https:\/\/doi.org\/10.1186\/s12885-019-6470-y(Epub 2020\/01\/01).","journal-title":"BMC Cancer."},{"issue":"41","key":"282_CR31","doi-asserted-by":"publisher","first-page":"70508","DOI":"10.18632\/oncotarget.19733","volume":"8","author":"L Yuan","year":"2017","unstructured":"Yuan L, Shu B, Chen L, Qian K, Wang Y, Qian G, et al. Overexpression of COL3A1 confers a poor prognosis in human bladder cancer identified by co-expression analysis. Oncotarget. 2017;8(41):70508\u201320. https:\/\/doi.org\/10.18632\/oncotarget.19733(Epub 2017\/10\/21).","journal-title":"Oncotarget."},{"issue":"2","key":"282_CR32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3233\/cbm-181940","volume":"24","author":"S Shi","year":"2019","unstructured":"Shi S, Tian B. Identification of biomarkers associated with progression and prognosis in bladder cancer via co-expression analysis. Cancer Biomark. 2019;24(2):183\u201393. https:\/\/doi.org\/10.3233\/cbm-181940(Epub 2019\/01\/29).","journal-title":"Cancer Biomark."},{"issue":"1","key":"282_CR33","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1186\/s12885-019-6084-4","volume":"19","author":"H Engqvist","year":"2019","unstructured":"Engqvist H, Parris TZ, Kovacs A, Nemes S, Werner Ronnerman E, De Lara S, et al. Immunohistochemical validation of COL3A1, GPR158 and PITHD1 as prognostic biomarkers in early-stage ovarian carcinomas. BMC Cancer. 2019;19(1):928. https:\/\/doi.org\/10.1186\/s12885-019-6084-4(Epub 2019\/09\/20).","journal-title":"BMC Cancer."},{"issue":"2","key":"282_CR34","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.3892\/ol.2018.8830","volume":"16","author":"YF Gao","year":"2018","unstructured":"Gao YF, Zhu T, Chen J, Liu L, Ouyang R. Knockdown of collagen alpha-1(III) inhibits glioma cell proliferation and migration and is regulated by miR128-3p. Oncol Lett. 2018;16(2):1917\u201323. https:\/\/doi.org\/10.3892\/ol.2018.8830(Epub 2018\/07\/17).","journal-title":"Oncol Lett."},{"key":"282_CR35","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12014-019-9257-x","volume":"16","author":"G Carpino","year":"2019","unstructured":"Carpino G, Overi D, Melandro F, Grimaldi A, Cardinale V, Di Matteo S, et al. Matrisome analysis of intrahepatic cholangiocarcinoma unveils a peculiar cancer-associated extracellular matrix structure. Clin Proteomics. 2019;16:37. https:\/\/doi.org\/10.1186\/s12014-019-9257-x(Epub 2019\/11\/07).","journal-title":"Clin Proteomics"},{"issue":"3","key":"282_CR36","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.celrep.2019.12.075","volume":"30","author":"H Ma","year":"2020","unstructured":"Ma H, Wang J, Zhao X, Wu T, Huang Z, Chen D, et al. Periostin promotes colorectal tumorigenesis through integrin-FAK-Src Pathway-mediated YAP\/TAZ activation. Cell Rep. 2020;30(3):793\u2013806. https:\/\/doi.org\/10.1016\/j.celrep.2019.12.075(Epub 2020\/01\/23).","journal-title":"Cell Rep."},{"issue":"1","key":"282_CR37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.20892\/j.issn.2095-3941.2018.0077","volume":"16","author":"L Chen","year":"2019","unstructured":"Chen L, Tian X, Gong W, Sun B, Li G, Liu D, et al. Periostin mediates epithelial-mesenchymal transition through the MAPK\/ERK pathway in hepatoblastoma. Cancer Biol Med. 2019;16(1):89\u2013100. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2018.0077(Epub 2019\/05\/24).","journal-title":"Cancer Biol Med."},{"issue":"4","key":"282_CR38","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.3892\/or.2020.7485","volume":"43","author":"J Sonongbua","year":"2020","unstructured":"Sonongbua J, Siritungyong S, Thongchot S, Kamolhan T, Utispan K, Thuwajit P, et al. Periostin induces epithelialtomesenchymal transition via the integrin alpha5beta1\/TWIST2 axis in cholangiocarcinoma. Oncol Rep. 2020;43(4):1147\u201358. https:\/\/doi.org\/10.3892\/or.2020.7485(Epub 2020\/02\/06).","journal-title":"Oncol Rep"},{"key":"282_CR39","doi-asserted-by":"publisher","DOI":"10.7554\/elife.33947","author":"EV Abel","year":"2018","unstructured":"Abel EV, Goto M, Magnuson B, Abraham S, Ramanathan N, Hotaling E, et al. HNF1A is a novel oncogene that regulates human pancreatic cancer stem cell properties. Elife. 2018. https:\/\/doi.org\/10.7554\/elife.33947(Epub 2018\/08\/04).","journal-title":"Elife."},{"issue":"1","key":"282_CR40","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41422-019-0259-z","volume":"30","author":"S Teng","year":"2020","unstructured":"Teng S, Li YE, Yang M, Qi R, Huang Y, Wang Q, et al. Tissue-specific transcription reprogramming promotes liver metastasis of colorectal cancer. Cell Res. 2020;30(1):34\u201349. https:\/\/doi.org\/10.1038\/s41422-019-0259-z(Epub 2019\/12\/08).","journal-title":"Cell Res"},{"key":"282_CR41","first-page":"15","volume-title":"Cytokeratins tools in oncology","author":"P Chougule","year":"2012","unstructured":"Chougule P, Sumitran-Holgersson S. Cytokeratins of the Liver and Intestine Epithelial Cells During Development and Disease. In: Hamilton G, editor. Cytokeratins tools in oncology. London: IntechOpen; 2012. p. 15\u201332."},{"issue":"12","key":"282_CR42","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1074\/mcp.m500279-mcp200","volume":"4","author":"M Uhlen","year":"2005","unstructured":"Uhlen M, Bjorling E, Agaton C, Szigyarto CA, Amini B, Andersen E, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics. 2005;4(12):1920\u201332. https:\/\/doi.org\/10.1074\/mcp.m500279-mcp200(Epub 2005\/08\/30).","journal-title":"Mol Cell Proteomics"},{"issue":"4","key":"282_CR43","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4251\/wjgo.v3.i4.49","volume":"3","author":"G Malaguarnera","year":"2011","unstructured":"Malaguarnera G, Giordano M, Paladina I, Rando A, Uccello M, Basile F, et al. Markers of bile duct tumors. World J Gastrointest Oncol. 2011;3(4):49\u201359. https:\/\/doi.org\/10.4251\/wjgo.v3.i4.49(Epub 2011\/04\/30).","journal-title":"World J Gastrointest Oncol."},{"issue":"1","key":"282_CR44","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.1038\/s41598-017-04164-z","volume":"7","author":"D Barnett","year":"2017","unstructured":"Barnett D, Liu Y, Partyka K, Huang Y, Tang H, Hostetter G, et al. The CA19-9 and Sialyl-TRA antigens define separate subpopulations of pancreatic cancer cells. Sci Rep. 2017;7(1):4020. https:\/\/doi.org\/10.1038\/s41598-017-04164-z(Epub 2017\/06\/24).","journal-title":"Sci Rep."},{"key":"282_CR45","doi-asserted-by":"publisher","first-page":"6","DOI":"10.2217\/fmeb2013.13.123","volume-title":"Mucins and Cancer","author":"MA McGuckin","year":"2013","unstructured":"McGuckin MA. Introduction to mucins in cancer. In: Taylor-Papadimitriou J, Burchell JM, editors. Mucins and Cancer. London: Future Medicine Ltd; 2013. p. 6\u201318."},{"issue":"50","key":"282_CR46","doi-asserted-by":"publisher","first-page":"e2286","DOI":"10.1097\/md.0000000000002286","volume":"94","author":"F Xu","year":"2015","unstructured":"Xu F, Liu F, Zhao H, An G, Feng G. Prognostic significance of mucin antigen MUC1 in various human epithelial cancers: a meta-analysis. Medicine. 2015;94(50):e2286. https:\/\/doi.org\/10.1097\/md.0000000000002286(Epub 2015\/12\/20).","journal-title":"Medicine."},{"key":"282_CR47","doi-asserted-by":"publisher","first-page":"9421571","DOI":"10.1155\/2016\/9421571","volume":"2016","author":"XT Wang","year":"2016","unstructured":"Wang XT, Kong FB, Mai W, Li L, Pang LM. MUC1 immunohistochemical expression as a prognostic factor in gastric cancer: meta-analysis. Dis Markers. 2016;2016:9421571. https:\/\/doi.org\/10.1155\/2016\/9421571(Epub 2016\/05\/18).","journal-title":"Dis Markers"},{"issue":"11","key":"282_CR48","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.neo.2017.06.006","volume":"19","author":"X Lin","year":"2017","unstructured":"Lin X, Gu Y, Kapoor A, Wei F, Aziz T, Ojo D, et al. Overexpression of MUC1 and genomic alterations in its network associate with prostate cancer progression. Neoplasia. 2017;19(11):857\u201367. https:\/\/doi.org\/10.1016\/j.neo.2017.06.006(Epub 2017\/09\/21).","journal-title":"Neoplasia."},{"issue":"52","key":"282_CR49","doi-asserted-by":"publisher","first-page":"90315","DOI":"10.18632\/oncotarget.19861","volume":"8","author":"X Huang","year":"2017","unstructured":"Huang X, Sun Q, Chen C, Zhang Y, Kang X, Zhang JY, et al. MUC1 overexpression predicts worse survival in patients with non-small cell lung cancer: evidence from an updated meta-analysis. Oncotarget. 2017;8(52):90315\u201326. https:\/\/doi.org\/10.18632\/oncotarget.19861(Epub 2017\/11\/23).","journal-title":"Oncotarget."},{"issue":"2","key":"282_CR50","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.advms.2018.04.002","volume":"63","author":"HEA Ozcan","year":"2018","unstructured":"Ozcan HEA, Anuk T, Ozden O. Expression profile and cellular localizations of mucin proteins, CK7, and cytoplasmic p27 in Barrett\u2019s esophagus and esophageal adenocarcinoma. Adv Med Sci. 2018;63(2):296\u2013300. https:\/\/doi.org\/10.1016\/j.advms.2018.04.002(Epub 2018\/05\/29).","journal-title":"Adv Med Sci."},{"issue":"86","key":"282_CR51","doi-asserted-by":"publisher","first-page":"35666","DOI":"10.18632\/oncotarget.26278","volume":"9","author":"A Saltos","year":"2018","unstructured":"Saltos A, Khalil F, Smith M, Li J, Schell M, Antonia SJ, et al. Clinical associations of mucin 1 in human lung cancer and precancerous lesions. Oncotarget. 2018;9(86):35666\u201375. https:\/\/doi.org\/10.18632\/oncotarget.26278(Epub 2018\/11\/28).","journal-title":"Oncotarget."},{"issue":"5","key":"282_CR52","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2220\/biomedres.35.295","volume":"35","author":"T Toba","year":"2014","unstructured":"Toba T, Kijima H, Hakamada K, Igarashi Y. Histological phenotype is correlated with the wall-invasion pattern of gallbladder adenocarcinoma. Biomed Res. 2014;35(5):295\u2013302 (Epub 2014\/10\/31).","journal-title":"Biomed Res"},{"issue":"6","key":"282_CR53","doi-asserted-by":"publisher","first-page":"585","DOI":"10.14670\/hh-11-824","volume":"32","author":"T Hiraki","year":"2017","unstructured":"Hiraki T, Yamada S, Higashi M, Hatanaka K, Yokoyama S, Kitazono I, et al. Immunohistochemical expression of mucin antigens in gallbladder adenocarcinoma: MUC1-positive and MUC2-negative expression Is associated with vessel invasion and shortened survival. Histol Histopathol. 2017;32(6):585\u201396. https:\/\/doi.org\/10.14670\/hh-11-824(Epub 2016\/09\/28).","journal-title":"Histol Histopathol"},{"issue":"5","key":"282_CR54","first-page":"1333","volume":"7","author":"T Kawamoto","year":"2001","unstructured":"Kawamoto T, Shoda J, Irimura T, Miyahara N, Furukawa M, Ueda T, et al. Expression of MUC1 mucins in the subserosal layer correlates with postsurgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder. Clin Cancer Res. 2001;7(5):1333\u201342 (Epub 2001\/05\/15).","journal-title":"Clin Cancer Res"},{"issue":"8","key":"282_CR55","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/j.1440-1827.2004.01666.x","volume":"54","author":"HJ Chang","year":"2004","unstructured":"Chang HJ, Kim SW, Lee BL, Hong EK, Kim WH. Phenotypic alterations of mucins and cytokeratins during gallbladder carcinogenesis. Pathol Int. 2004;54(8):576\u201384. https:\/\/doi.org\/10.1111\/j.1440-1827.2004.01666.x(Epub 2004\/07\/21).","journal-title":"Pathol Int"},{"issue":"8","key":"282_CR56","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.ejso.2005.03.008","volume":"31","author":"M Ghosh","year":"2005","unstructured":"Ghosh M, Kamma H, Kawamoto T, Koike N, Miwa M, Kapoor VK, et al. MUC 1 core protein as a marker of gallbladder malignancy. Eur J Surg Oncol. 2005;31(8):891\u20136. https:\/\/doi.org\/10.1016\/j.ejso.2005.03.008(Epub 2005\/06\/01).","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"282_CR57","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jso.22055","volume":"105","author":"L Xiong","year":"2012","unstructured":"Xiong L, Yang Z, Yang L, Liu J, Miao X. Expressive levels of MUC1 and MUC5AC and their clinicopathologic significances in the benign and malignant lesions of gallbladder. J Surg Oncol. 2012;105(1):97\u2013103. https:\/\/doi.org\/10.1002\/jso.22055(Epub 2011\/08\/05).","journal-title":"J Surg Oncol"},{"issue":"1","key":"282_CR58","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/(sici)1096-9896(199905)188:1<30::aid-path291>3.0.co;2-q","volume":"188","author":"T Yamato","year":"1999","unstructured":"Yamato T, Sasaki M, Watanabe Y, Nakanuma Y. Expression of MUC1 and MUC2 mucin core proteins and their messenger RNA in gall bladder carcinoma: an immunohistochemical and in situ hybridization study. J Pathol. 1999;188(1):30\u20137. https:\/\/doi.org\/10.1002\/(sici)1096-9896(199905)188:1%3c30:aid-path291%3e3.0.co;2-q(Epub 1999\/07\/09).","journal-title":"J Pathol."},{"issue":"9","key":"282_CR59","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrc3982","volume":"15","author":"SS Pinho","year":"2015","unstructured":"Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15(9):540\u201355. https:\/\/doi.org\/10.1038\/nrc3982(Epub 2015\/08\/21).","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"282_CR60","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/ni.3552","volume":"17","author":"R Beatson","year":"2016","unstructured":"Beatson R, Tajadura-Ortega V, Achkova D, Picco G, Tsourouktsoglou TD, Klausing S, et al. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nat Immunol. 2016;17(11):1273\u201381. https:\/\/doi.org\/10.1038\/ni.3552(Epub 2016\/10\/21).","journal-title":"Nat Immunol"},{"issue":"7","key":"282_CR61","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/j.1442-2042.2005.01112.x","volume":"12","author":"T Arai","year":"2005","unstructured":"Arai T, Fujita K, Fujime M, Irimura T. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis. Int J Urol. 2005;12(7):654\u201361. https:\/\/doi.org\/10.1111\/j.1442-2042.2005.01112.x(Epub 2005\/07\/28).","journal-title":"Int J Urol"},{"issue":"28","key":"282_CR62","first-page":"2240","volume":"46","author":"Y Masaki","year":"1999","unstructured":"Masaki Y, Oka M, Ogura Y, Ueno T, Nishihara K, Tangoku A, et al. Sialylated MUC1 mucin expression in normal pancreas, benign pancreatic lesions, and pancreatic ductal adenocarcinoma. Hepatogastroenterology. 1999;46(28):2240\u20135 (Epub 1999\/10\/16).","journal-title":"Hepatogastroenterology"},{"issue":"10","key":"282_CR63","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.humpath.2012.01.005","volume":"43","author":"MM Streppel","year":"2012","unstructured":"Streppel MM, Vincent A, Mukherjee R, Campbell NR, Chen SH, Konstantopoulos K, et al. Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon. Hum Pathol. 2012;43(10):1755\u201363. https:\/\/doi.org\/10.1016\/j.humpath.2012.01.005(Epub 2012\/05\/01).","journal-title":"Hum Pathol"},{"issue":"11","key":"282_CR64","doi-asserted-by":"publisher","first-page":"e0166067","DOI":"10.1371\/journal.pone.0166067","volume":"11","author":"C Fernandez Moro","year":"2016","unstructured":"Fernandez Moro C, Fernandez-Woodbridge A, Alistair D\u2019souza M, Zhang Q, Bozoky B, Kandaswamy SV, et al. Immunohistochemical typing of adenocarcinomas of the pancreatobiliary system improves diagnosis and prognostic stratification. PLoS ONE. 2016;11(11):e0166067. https:\/\/doi.org\/10.1371\/journal.pone.0166067(Epub 2016\/11\/10).","journal-title":"PLoS ONE"},{"issue":"8","key":"282_CR65","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/jso.20534","volume":"93","author":"A Chaube","year":"2006","unstructured":"Chaube A, Tewari M, Singh U, Shukla HS. CA 125: a potential tumor marker for gallbladder cancer. J Surg Oncol. 2006;93(8):665\u20139 (Epub 2006\/05\/26).","journal-title":"J Surg Oncol"},{"issue":"3","key":"282_CR66","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1046\/j.1365-2559.1997.2420850.x","volume":"31","author":"I Roa","year":"1997","unstructured":"Roa I, Villaseca M, Araya J, Roa J, de Aretxabala X, Melo A, et al. p53 tumour suppressor gene protein expression in early and advanced gallbladder carcinoma. Histopathology. 1997;31(3):226\u201330 (Epub 1997\/11\/14).","journal-title":"Histopathology"},{"issue":"2","key":"282_CR67","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/s1607-551x(09)70221-9","volume":"22","author":"SN Wang","year":"2006","unstructured":"Wang SN, Chung SC, Tsai KB, Chai CY, Chang WT, Kuo KK, et al. Aberrant p53 expression and the development of gallbladder carcinoma and adenoma. Kaohsiung J Med Sci. 2006;22(2):53\u20139. https:\/\/doi.org\/10.1016\/s1607-551x(09)70221-9(Epub 2006\/03\/30).","journal-title":"Kaohsiung J Med Sci"},{"issue":"3","key":"282_CR68","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/13651820410025110","volume":"6","author":"LA Hidalgo Grau","year":"2004","unstructured":"Hidalgo Grau LA, Badia JM, Salvador CA, Monso TS, Canaleta JF, Nogues JM, et al. Gallbladder carcinoma: the role of p53 protein overexpression and Ki-67 antigen expression as prognostic markers. HPB. 2004;6(3):174\u201380. https:\/\/doi.org\/10.1080\/13651820410025110(Epub 2008\/03\/12).","journal-title":"HPB."},{"issue":"4","key":"282_CR69","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S0046-8177(96)90109-4","volume":"27","author":"II Wistuba","year":"1996","unstructured":"Wistuba II, Gazdar AF, Roa I, Albores-Saavedra J. p53 protein overexpression in gallbladder carcinoma and its precursor lesions: an immunohistochemical study. Hum Pathol. 1996;27(4):360\u20135 (Epub 1996\/04\/01).","journal-title":"Hum Pathol"},{"key":"282_CR70","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/modpathol.2011.85","volume":"24","author":"A Yemelyanova","year":"2011","unstructured":"Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih IM, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol. 2011;24:1248. https:\/\/doi.org\/10.1038\/modpathol.2011.85.","journal-title":"Mod Pathol"},{"issue":"40","key":"282_CR71","doi-asserted-by":"publisher","first-page":"64910","DOI":"10.18632\/oncotarget.11912","volume":"7","author":"B Murnyak","year":"2016","unstructured":"Murnyak B, Hortobagyi T. Immunohistochemical correlates of TP53 somatic mutations in cancer. Oncotarget. 2016;7(40):64910\u201320. https:\/\/doi.org\/10.18632\/oncotarget.11912(Epub 2016\/09\/15).","journal-title":"Oncotarget."},{"issue":"4","key":"282_CR72","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/1097-0215(20010720)95:4<232::aid-ijc1040>3.0.co;2-5","volume":"95","author":"T Koga","year":"2001","unstructured":"Koga T, Hashimoto S, Sugio K, Yoshino I, Nakagawa K, Yonemitsu Y, et al. Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation. Int J Cancer. 2001;95(4):232\u20139. https:\/\/doi.org\/10.1002\/1097-0215(20010720)95:4%3c232:aid-ijc1040%3e3.0.co;2-5(Epub 2001\/06\/16).","journal-title":"Int J Cancer"},{"issue":"1","key":"282_CR73","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1200\/jco.2005.03.139","volume":"23","author":"YC Wang","year":"2005","unstructured":"Wang YC, Lin RK, Tan YH, Chen JT, Chen CY, Wang YC. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer. J Clin Oncol. 2005;23(1):154\u201364. https:\/\/doi.org\/10.1200\/jco.2005.03.139(Epub 2004\/12\/31).","journal-title":"J Clin Oncol"},{"issue":"7","key":"282_CR74","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/j.1440-1746.2004.03357.x","volume":"19","author":"H Kalekou","year":"2004","unstructured":"Kalekou H, Miliaras D. Immunohistochemical study of microvessel density, CD44 (standard form), p53 protein and c-erbB2 in gallbladder carcinoma. J Gastroenterol Hepatol. 2004;19(7):812\u20138. https:\/\/doi.org\/10.1111\/j.1440-1746.2004.03357.x(Epub 2004\/06\/24).","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"282_CR75","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/path.1779","volume":"206","author":"K Nakazawa","year":"2005","unstructured":"Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol. 2005;206(3):356\u201365. https:\/\/doi.org\/10.1002\/path.1779(Epub 2005\/05\/14).","journal-title":"J Pathol."},{"issue":"6","key":"282_CR76","first-page":"221","volume":"1","author":"T Kawamoto","year":"2007","unstructured":"Kawamoto T, Krishnamurthy S, Tarco E, Trivedi S, Wistuba II, Li D, et al. HER receptor family: novel candidate for targeted therapy for gallbladder and extrahepatic bile duct cancer. Gastrointest Cancer Res. 2007;1(6):221\u20137 (Epub 2007\/11\/01).","journal-title":"Gastrointest Cancer Res."},{"issue":"36","key":"282_CR77","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.3748\/wjg.15.4511","volume":"15","author":"J Harder","year":"2009","unstructured":"Harder J, Waiz O, Otto F, Geissler M, Olschewski M, Weinhold B, et al. EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol. 2009;15(36):4511\u20137 (Epub 2009\/09\/25).","journal-title":"World J Gastroenterol"},{"issue":"2","key":"282_CR78","first-page":"42","volume":"7","author":"I Roa","year":"2014","unstructured":"Roa I, de Toro G, Schalper K, de Aretxabala X, Churi C, Javle M. Overexpression of the HER2\/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer. Gastrointest Cancer Res. 2014;7(2):42\u20138 (Epub 2014\/05\/07).","journal-title":"Gastrointest Cancer Res."},{"issue":"8","key":"282_CR79","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/ng.3030","volume":"46","author":"M Li","year":"2014","unstructured":"Li M, Zhang Z, Li X, Ye J, Wu X, Tan Z, et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet. 2014;46(8):872\u20136. https:\/\/doi.org\/10.1038\/ng.3030(Epub 2014\/07\/07).","journal-title":"Nat Genet"},{"issue":"19","key":"282_CR80","first-page":"6971","volume":"61","author":"K Kiguchi","year":"2001","unstructured":"Kiguchi K, Carbajal S, Chan K, Beltran L, Ruffino L, Shen J, et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res. 2001;61(19):6971\u20136 (Epub 2001\/10\/05).","journal-title":"Cancer Res"},{"issue":"8","key":"282_CR81","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1158\/0008-5472.can-06-3214","volume":"67","author":"Q Wu","year":"2007","unstructured":"Wu Q, Kiguchi K, Kawamoto T, Ajiki T, Traag J, Carbajal S, et al. Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. Cancer Res. 2007;67(8):3794\u2013800. https:\/\/doi.org\/10.1158\/0008-5472.can-06-3214(Epub 2007\/04\/19).","journal-title":"Cancer Res"},{"issue":"5","key":"282_CR82","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/j.1365-2559.2011.04012.x","volume":"59","author":"MA Kim","year":"2011","unstructured":"Kim MA, Lee HJ, Yang HK, Bang YJ, Kim WH. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology. 2011;59(5):822\u201331. https:\/\/doi.org\/10.1111\/j.1365-2559.2011.04012.x(Epub 2011\/11\/19).","journal-title":"Histopathology"},{"issue":"7","key":"282_CR83","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/modpathol.2012.36","volume":"25","author":"H Seol","year":"2012","unstructured":"Seol H, Lee HJ, Choi Y, Lee HE, Kim YJ, Kim JH, et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod Pathol. 2012;25(7):938\u201348. https:\/\/doi.org\/10.1038\/modpathol.2012.36(Epub 2012\/03\/06).","journal-title":"Mod Pathol"},{"issue":"32","key":"282_CR84","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.1200\/jco.2012.43.1890","volume":"30","author":"HH Yoon","year":"2012","unstructured":"Yoon HH, Shi Q, Sukov WR, Lewis MA, Sattler CA, Wiktor AE, et al. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol. 2012;30(32):3932\u20138. https:\/\/doi.org\/10.1200\/jco.2012.43.1890(Epub 2012\/09\/19).","journal-title":"J Clin Oncol"},{"issue":"5","key":"282_CR85","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/modpathol.2012.205","volume":"26","author":"EY Cho","year":"2013","unstructured":"Cho EY, Park K, Do I, Cho J, Kim J, Lee J, et al. Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas. Mod Pathol. 2013;26(5):677\u201384. https:\/\/doi.org\/10.1038\/modpathol.2012.205(Epub 2012\/12\/15).","journal-title":"Mod Pathol"},{"issue":"1","key":"282_CR86","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10549-016-3856-2","volume":"158","author":"S Kurozumi","year":"2016","unstructured":"Kurozumi S, Padilla M, Kurosumi M, Matsumoto H, Inoue K, Horiguchi J, et al. HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients. Breast Cancer Res Treat. 2016;158(1):99\u2013111. https:\/\/doi.org\/10.1007\/s10549-016-3856-2(Epub 2016\/06\/20).","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"282_CR87","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10549-017-4453-8","volume":"166","author":"Y Hou","year":"2017","unstructured":"Hou Y, Nitta H, Wei L, Banks PM, Portier B, Parwani AV, et al. HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma. Breast Cancer Res Treat. 2017;166(2):447\u201357. https:\/\/doi.org\/10.1007\/s10549-017-4453-8(Epub 2017\/08\/12).","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"282_CR88","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1002\/1878-0261.12375","volume":"12","author":"IH Rye","year":"2018","unstructured":"Rye IH, Trinh A, Saetersdal AB, Nebdal D, Lingjaerde OC, Almendro V, et al. Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors. Mol Oncol. 2018;12(11):1838\u201355. https:\/\/doi.org\/10.1002\/1878-0261.12375(Epub 2018\/08\/23).","journal-title":"Mol Oncol."},{"issue":"3","key":"282_CR89","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00428-010-0952-2","volume":"457","author":"J Ruschoff","year":"2010","unstructured":"Ruschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010;457(3):299\u2013307. https:\/\/doi.org\/10.1007\/s00428-010-0952-2(Epub 2010\/07\/29).","journal-title":"Virchows Arch"},{"issue":"6","key":"282_CR90","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/bioinformatics\/btr026","volume":"27","author":"R Schmieder","year":"2011","unstructured":"Schmieder R, Edwards R. Quality control and preprocessing of metagenomic datasets. Bioinformatics. 2011;27(6):863\u20134. https:\/\/doi.org\/10.1093\/bioinformatics\/btr026(Epub 2011\/02\/01).","journal-title":"Bioinformatics"},{"issue":"1","key":"282_CR91","doi-asserted-by":"publisher","first-page":"3","DOI":"10.14806\/ej.17.1.200","volume":"17","author":"M Martin","year":"2011","unstructured":"Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. %J EMBnet journal. 2011;17(1):3. https:\/\/doi.org\/10.14806\/ej.17.1.200(Epub 2011-08-02).","journal-title":"%J EMBnet journal."},{"issue":"1","key":"282_CR92","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15\u201321. https:\/\/doi.org\/10.1093\/bioinformatics\/bts635(Epub 2012\/10\/30).","journal-title":"Bioinformatics"},{"issue":"9","key":"282_CR93","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297\u2013303. https:\/\/doi.org\/10.1101\/gr.107524.110(Epub 2010\/07\/21).","journal-title":"Genome Res"},{"issue":"16","key":"282_CR94","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164. https:\/\/doi.org\/10.1093\/nar\/gkq603(Epub 2010\/07\/06).","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"282_CR95","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923\u201330. https:\/\/doi.org\/10.1093\/bioinformatics\/btt656(Epub 2013\/11\/15).","journal-title":"Bioinformatics"},{"issue":"7571","key":"282_CR96","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature15393","volume":"526","author":"A Auton","year":"2015","unstructured":"Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68\u201374. https:\/\/doi.org\/10.1038\/nature15393(Epub 2015\/10\/04).","journal-title":"Nature"},{"issue":"9","key":"282_CR97","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1101\/gr.094052.109","volume":"19","author":"DH Alexander","year":"2009","unstructured":"Alexander DH, Novembre J, Lange K. Fast model-based estimation of ancestry in unrelated individuals. Genome Res. 2009;19(9):1655\u201364. https:\/\/doi.org\/10.1101\/gr.094052.109(Epub 2009\/08\/04).","journal-title":"Genome Res"}],"container-title":["Biological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40659-020-00282-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40659-020-00282-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40659-020-00282-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T23:23:46Z","timestamp":1618442626000},"score":1,"resource":{"primary":{"URL":"https:\/\/biolres.biomedcentral.com\/articles\/10.1186\/s40659-020-00282-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["282"],"URL":"https:\/\/doi.org\/10.1186\/s40659-020-00282-7","relation":{},"ISSN":["0717-6287"],"issn-type":[{"value":"0717-6287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"11 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The present study was approved by the Scientific Ethics Committee of the Faculty of Medicine, Pontificia Universidad Cat\u00f3lica de Chile, and was conducted in accordance with the tenets of the 1964 Helsinki declaration and its subsequent amendments. The clinical sample used to develop and establish the primary culture was obtained after the patient signed the written informed consent form. Mouse husbandry and animal experiments were conducted in accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. For injections of cancer cells, mice were anesthetized under 3% isoflurane for induction of anesthesia and 1.5% for maintenance. At the end of the assay, mice were euthanized using carbon dioxide (CO<sub>2<\/sub>) overdose. The protocol was approved by the Committee on Animal Experimentation, Pontificia Universidad Cat\u00f3lica de Chile (Protocol No CBB-224\/2014).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}